QQQ   424.06 (-0.76%)
AAPL   181.52 (-0.02%)
MSFT   399.57 (-0.80%)
META   468.16 (-0.66%)
GOOGL   142.25 (+0.80%)
AMZN   167.92 (+0.50%)
TSLA   193.54 (-0.11%)
NVDA   673.07 (-3.09%)
NIO   6.03 (+1.17%)
AMD   163.77 (-1.16%)
BABA   75.71 (+3.51%)
T   16.95 (+0.24%)
F   12.08 (-1.39%)
MU   80.64 (-0.09%)
CGC   3.40 (-3.95%)
GE   148.44 (-0.12%)
DIS   107.70 (-1.59%)
AMC   4.57 (-1.93%)
PFE   27.45 (-0.51%)
PYPL   57.74 (-1.52%)
XOM   104.43 (+1.64%)
QQQ   424.06 (-0.76%)
AAPL   181.52 (-0.02%)
MSFT   399.57 (-0.80%)
META   468.16 (-0.66%)
GOOGL   142.25 (+0.80%)
AMZN   167.92 (+0.50%)
TSLA   193.54 (-0.11%)
NVDA   673.07 (-3.09%)
NIO   6.03 (+1.17%)
AMD   163.77 (-1.16%)
BABA   75.71 (+3.51%)
T   16.95 (+0.24%)
F   12.08 (-1.39%)
MU   80.64 (-0.09%)
CGC   3.40 (-3.95%)
GE   148.44 (-0.12%)
DIS   107.70 (-1.59%)
AMC   4.57 (-1.93%)
PFE   27.45 (-0.51%)
PYPL   57.74 (-1.52%)
XOM   104.43 (+1.64%)
QQQ   424.06 (-0.76%)
AAPL   181.52 (-0.02%)
MSFT   399.57 (-0.80%)
META   468.16 (-0.66%)
GOOGL   142.25 (+0.80%)
AMZN   167.92 (+0.50%)
TSLA   193.54 (-0.11%)
NVDA   673.07 (-3.09%)
NIO   6.03 (+1.17%)
AMD   163.77 (-1.16%)
BABA   75.71 (+3.51%)
T   16.95 (+0.24%)
F   12.08 (-1.39%)
MU   80.64 (-0.09%)
CGC   3.40 (-3.95%)
GE   148.44 (-0.12%)
DIS   107.70 (-1.59%)
AMC   4.57 (-1.93%)
PFE   27.45 (-0.51%)
PYPL   57.74 (-1.52%)
XOM   104.43 (+1.64%)
QQQ   424.06 (-0.76%)
AAPL   181.52 (-0.02%)
MSFT   399.57 (-0.80%)
META   468.16 (-0.66%)
GOOGL   142.25 (+0.80%)
AMZN   167.92 (+0.50%)
TSLA   193.54 (-0.11%)
NVDA   673.07 (-3.09%)
NIO   6.03 (+1.17%)
AMD   163.77 (-1.16%)
BABA   75.71 (+3.51%)
T   16.95 (+0.24%)
F   12.08 (-1.39%)
MU   80.64 (-0.09%)
CGC   3.40 (-3.95%)
GE   148.44 (-0.12%)
DIS   107.70 (-1.59%)
AMC   4.57 (-1.93%)
PFE   27.45 (-0.51%)
PYPL   57.74 (-1.52%)
XOM   104.43 (+1.64%)
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

$29.25
+0.03 (+0.10%)
(As of 01:04 PM ET)
Today's Range
$29.01
$29.62
50-Day Range
$26.90
$39.48
52-Week Range
$20.67
$42.48
Volume
245,768 shs
Average Volume
1.66 million shs
Market Capitalization
$3.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.25

Arrowhead Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.62 Rating Score
Upside/​Downside
75.2% Upside
$51.25 Price Target
Short Interest
Healthy
6.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
1.22mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$5.90 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.70) to ($2.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Medical Sector

72nd out of 932 stocks

Pharmaceutical Preparations Industry

24th out of 431 stocks


ARWR stock logo

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

ARWR Stock Price History

ARWR Stock News Headlines

ARWR Mar 2024 30.000 call
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call
Arrowhead Pharmaceuticals Inc Insider Sells Shares
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Today
2/21/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARWR
Employees
525
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.25
High Stock Price Target
$90.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+75.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
13 Analysts

Profitability

Net Income
$-205,270,000.00
Net Margins
-163.32%
Pretax Margin
-166.93%

Debt

Sales & Book Value

Annual Sales
$240.74 million
Book Value
$1.40 per share

Miscellaneous

Free Float
118,322,000
Market Cap
$3.62 billion
Optionable
Optionable
Beta
0.78
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 55)
    CEO, President & Director
    Comp: $1.6M
  • Mr. Kenneth A. MyszkowskiMr. Kenneth A. Myszkowski (Age 58)
    Chief Financial Officer
    Comp: $834.34k
  • Mr. Patrick O'Brien J.D. (Age 60)
    PharmD, COO, General Counsel & Secretary
    Comp: $835.14k
  • Dr. James C. Hamilton M.D. (Age 46)
    MBA, Chief of Discovery & Translational Medicine
    Comp: $762.14k
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Bruce D. Given M.D. (Age 70)
    Chief Medical Scientist
    Comp: $486.31k
  • Dr. Mark Seefeld (Age 70)
    Head of Toxicology & VP
  • Ms. Tracie OliverMs. Tracie Oliver (Age 62)
    Chief Commercial Officer
    Comp: $449.58k














ARWR Stock Analysis - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price target for 2024?

13 analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' shares. Their ARWR share price targets range from $27.00 to $90.00. On average, they anticipate the company's share price to reach $51.25 in the next twelve months. This suggests a possible upside of 75.2% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2024?

Arrowhead Pharmaceuticals' stock was trading at $30.60 at the start of the year. Since then, ARWR shares have decreased by 4.4% and is now trading at $29.25.
View the best growth stocks for 2024 here
.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totaling 7,720,000 shares, a decline of 13.0% from the January 15th total of 8,870,000 shares. Based on an average trading volume of 1,550,000 shares, the days-to-cover ratio is presently 5.0 days.
View Arrowhead Pharmaceuticals' Short Interest
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its earnings results on Tuesday, February, 6th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by $0.46. The biotechnology company had revenue of $3.55 million for the quarter, compared to analysts' expectations of $35.60 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 90.77% and a negative net margin of 163.32%. The business's quarterly revenue was down 94.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.39) EPS.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.61%), Norges Bank (1.07%), Capital International Investors (1.03%), Northern Trust Corp (0.99%), Avoro Capital Advisors LLC (0.91%) and Goldman Sachs Group Inc. (0.86%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARWR) was last updated on 2/21/2024 by MarketBeat.com Staff